Document Type : Original Article
Authors
1
Department of Molecular Biology, Molecular Biology Research & Studies Institute, Assiut University, Assiut 71511, Egypt
2
Department of Molecular biology, Molecular Biology Research & Studies Institute, Assiut University, Assiut 71511, Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Egypt
3
Department of Surgical Oncology, South Egypt Cancer Institute, Assiut University, Assiut 71511, Egypt
4
South Egypt Cancer Institute, Medical Oncology and Hematological Malignancies, Assiut University, Assiut 71511, Egypt
5
Department of Molecular Biology, Molecular Biology Research & Studies Institute, Assiut University, Assiut 71511, Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Egypt
Abstract
The third most prevalent cancer in the world is colorectal cancer [CRC]. Although the expression of the new immunological checkpoint V-domain Ig suppressor of T-cell activation [VISTA] in CRC has shown promise as a target for cancer treatment, its prognostic value is yet unknown. This work examined VISTA expression on lymphocytes, monocytes, and granulocytes in peripheral blood [PB] from CRC patients by flow cytometric staining. Analysis set up on the relationships between the expression of VISTA and clinicopathologic and laboratory characteristics. The study included 31 patients with CRC and 25 healthy controls. All participants subjected to full history taking, clinical examination, routine laboratory investigations, and flow cytometric detection of VISTA expression on lymphocytes, monocytes, and granulocytes in the PB. The expression of VISTA on neutrophils, monocytes, and lymphocytes was significantly increased in the PB of CRC patients compared to the normal controls. Also, the expression of VISTA on monocytes was considerably higher than its expression on granulocytes and lymphocytes, and its expression on granulocytes was higher than its expression on lymphocytes in the PB of both CRC patients and the normal controls. Our findings prove increased expression of VISTA on circulating leukocytes in CRC patients, particularly in those with complications such as perforation and obstruction. While this supports further investigation into VISTA's role in CRC immunoregulation, additional studies needed to validate its potential as a therapeutic target.
Keywords
)
View on SCiNiTO